tbuckley/cabot-search huggingface dataset:
L-carnitine supplementation in cancer patients with fatigue and carnitine deficiency
Authors: R. A. Cruciani, E. Dvorkin, P. Homel, B. Culliney, S. Malamud, S. Fleishman, J. Lapin, P. Lesage, R. Portenoy, N. V. Cruciani-Esteban
Journal: Journal of Clinical Oncology (2004)

8025 Background: Fatigue is highly prevalent in the cancer population and nutritional factors are among the postulated causes. Deficiency of the micronutrient L-carnitine could play a role by reducing energy production through fatty acid oxidation. We are presenting preliminary data of an open-label, dose-finding study to determine safety of one week L-carnitine supplementation in cancer patients with fatigue and carnitine deficiency. Methods: Patients with cancer, fatigue and carnitine deficiency, >18 years, Karnofsky score >50, and at least one week after completion of chemotherapy, were accrued. Carnitine deficiency= free carnitine <35 mmols/L for males and <25 for females or a ratio of acyl-carnitine (total -free)/free>0.4. A standard up-down dose finding design was utilized to determine the MTD of L-carnitine given by mouth. The beginning dose was 250 mg/day; doses were increased by 500 mg up to 3000 mg/day. Three patients were enrolled at each dose level. Fatigue (BFI), depressed mood (CES-D), quality of sleep (ESS), and performance status (Karnofsky Performance Status), were assessed at baseline and after one week of L-carnitine supplementation. Results: 18 patients that fulfilled predictors for carnitine deficiency (decreased caloric intake and muscle mass) were accrued to date. 14 (age range=34–67, females=6) were deficient (78%). Three dose levels of 3 patients completed 250, 750, and 1250 mg/day. There were no adverse effects. Preliminary analysis showed mean (SD) total carnitine increment from 27.7 (7.6) to 38.1 (9) after one week of supplementation (p=0.02); free carnitine increased from 23.0 (6.2) to 30.9 (6.8) (p=0.01). Mean (SD) BFI score was 71.1 (11.0) and 43.7 (27.9) after one week (p=0.018). Median (min, max) CES-D and ESS were 31.3 (16,48), 17.5 (0, 24) and 22.0 (6, 40)(p=0.01) and 8 (0,15)(p=0.027)after one week respectively. Median Karnofsky did not change significantly (p=0.32). Conclusions: The prevalence of carnitine deficiency in this study population was (78%). This study suggests that L-carnitine supplementation is safe up to 1250 mg /day and this dose may improve fatigue, mood, sleep in cancer patients with carnitine deficiency. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ligand Pharmaceuticals Sigma Thau; UCB Pharma; Ligand; Pfizer; Perdue
Maternal Immune Response to Fetal Platelet GPIbα Causes More Frequent Miscarriage in An Animal Model: A Potential Explanation for Low Reported Incidence of Fetal and Neonatal Immune Thrombocytopenia Mediated by Anti-GPIbα Antibodies.
Authors: Conglei Li, Siavash Piran, Pingguo Chen, Sean Lang, Jerry Ware, Zaverio M. Ruggeri, John Freedman, Heyu Ni
Journal: Blood (2008)
Flow Cytometric Detection of Asparagine Synthetase Protein in Leukemia Cells; Indication for L-Asparaginase Therapy
Authors: Toshiyuki Kitoh, Kou Suchan Gao Siqiang, Hidefumi Kato, Kenji Miyata, Yasuto Shimomura, Toshinori Hori, Kimiyoshi Sakaguchi, Yasuo Horikoshi, Kentarou Ohki, Katsuyoshi Koh, Takao Hamakubo
Journal: Blood (2014)
TCT-712 Immediate and mid-term impact of successful percutaneous transvenous mitral commissurotomy on right ventricular systolic function
Authors: Ayoub El hammiri, Asadi Amina, Sanaa Benhaourech, Farah Korchi, Marouane Allouch, Leila Azzouzi, Rachida Habbal
Journal: Journal of the American College of Cardiology (2015)
The Use of High Resolution Melting (HRM) Analysis for Molecular Gene Defects of Type 3 Von Willebrand Disease: Studies of An Italian Cohort of 10 Patients.
Authors: Maria Solimando, Augusto B. Federici, Luciano Baronciani, Alberto Mussetti, Margherita Punzo, Silvia La Marca, Manuela Platè, Rosanna Asselta, Pier Mannuccio Mannucci
Journal: Blood (2009)
USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation
Authors: Sabrina Torre, Maria J Polyak, David Langlais, Nassima Fodil, James M Kennedy, Irena Radovanovic, Joanne Berghout, Gabriel A Leiva-Torres, Connie M Krawczyk, Subburaj Ilangumaran, Karen Mossman, Chen Liang, Klaus-Peter Knobeloch, Luke M Healy, Jack Antel, Nathalie Arbour, Alexandre Prat, Jacek Majewski, Mark Lathrop, Silvia M Vidal, Philippe Gros
Journal: Nature Immunology (2016)
Hereditary Hemolytic Anemia in Korea From 1997 to 2011: A Study by the Korean Hereditary Hemolytic Anemia Working Party of the Korean Society of Hematology
Authors: Eun Sil Park, Hye Lim Jung, Hee Soon Cho, Jeong-Ok Hah, Sung Sup Park, Hong Hoe Koo, Moon Kyu Kim, Yeo-Kyeoung Kim, Young Dae Kim, Hee Jin Kim, Heung Sik Kim, Soon Ki Kim, Jong Jin Seo, Moon-Woo Seong, Sang Hoon Song, Hee Young Shin, Hyo Seop Ahn, Eun Sun Yoo, Chuhl Joo Lyu, Hoi Soo Yoon, Kun Soo Lee, Mee Jeong Lee, Young Tak Lim, Ho Joon Im, Dae Chul Jeong, Eun Jin Choi, Hyoung Soo Choi, Dong kyun Han, Hee Won Chueh
Journal: Blood (2012)
A Cost-Utility Analysis of Deferiprone Compared to Desferrioxamine and Deferasirox for the Treatment of Chronic Myocardial Iron Overload in Thalassemia Patients
Authors: Alessia Pepe, Aishah Hanif, Anthony Bentley, Roderick Walker, Ludovica Frizziero, Maria Caterina Putti, Anna Spasiano, Caterina Borgna-Pignatti, Aurelio Maggio, Maria Giovanna Neri, Antonella Meloni
Journal: Blood (2015)
TCT-215 Uninterrupted Novel Oral Anticoagulants and Warfarin Use for Peri-procedural Anticoagulation during Atrial Fibrillation Ablation
Authors: Arun K. Kanmanthareddy, Avanija R. Buddam, Madhu Reddy, Venkata M. Alla, Claire Hunter, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2015)
The Biological Function of DNA Hypermethylation in Murine MDS Model Lacking Tet2 and Ezh2
Authors: Nagisa Hasegawa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Kotaro Yokote, Atsushi Iwama
Journal: Blood (2014)
Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations
Authors: Zohar Sachs, Ernesto Diaz-Flores, Miechaleen D Diers, Karen Sachs, Sean C Bendall, Harris G Fienberg, Susan K Rathe, Garry P. Nolan, Kevin Shannon, David Largaespada
Journal: Blood (2010)
Chromosome Aberrations in 130 Patients with Multiple Myeloma Detected by Interphase FISH and Their Diagnostic and Prognostic Relevance.
Authors: Axel Glasmacher, Corinna Hahn, Andrea Juttner, Regine Schubert, Barbara Busert, Gesa Schwanitz, Ingo G.H. Schmidt-Wolf
Journal: Blood (2004)
Clinicians’ attitudes and preferences in choosing the first line drug for metastatic castration resistant prostate cancer (mCRPC): Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) in the clinical practice.
Authors: Orazio Caffo, Cinzia Ortega, Teodoro Sava, Cosimo Sacco, Sandro Barni, Paola Ermacora, Francesca La Russa, Francesca Maines, Veronica Prati, Fiorella Ruatta, Antonello Veccia, Enzo Galligioni
Journal: Journal of Clinical Oncology (2016)

332 Background: For one decade, docetaxel (DOC) represented the only therapeutic option for mCRPC pts. Recently, AA and enzalutamide demonstrated a survival gain in first line setting. Lacking direct comparison with DOC and considering some differences in selection criteria of the pivotal trials, the choice between DOC and these hormonal agents, which have a quite different toxicity profile, is often driven by pts’ characteristics and feelings and by clinicians’ attitudes and preferences as well. To date, only AA is available in Italy, from September 2014, for the first line setting and the present study explores the attitudes and preferences of clinicians in choosing between DOC and AA. Methods: We retrospectively reviewed the clinical records of all mCRPC pts who received a first-line treatment in 5 Italian hospitals after the introduction of AA in the clinical practice. All pts were treated with AA 1,000 mg po + prednisone (PDN) 10 mg po daily or with DOC at the dose of 75 mg/sqm i.v. every three wks. For each pt we have recorded the pre-first line clinical history and the baseline characteristics. Results: From September 2014 to August 2015, we collected a consecutive series of 70 mCRPC pts: 49 received AA, 21 DOC. The median age was 74 yrs (range 46-90), 6% had visceral mets; 8% had a performance status 2; 47% had pain. Pts treated with AA were significantly older (75.8 vs 69.7 yrs; p = 0.002); received more previous hormone therapies (2.19 vs 1.76; p = 0.03), had a longer interval between first hormone therapy and the start of mCRPC first line (47.6 vs 21.2 mos; p = 0.01) and finally, were less frequently symptomatic (27% vs 67%; p = 0.02%). Conclusions: The present study is the first to explore the clinicians’ attitudes and preferences, in the routine clinical practice, in choosing the first line drug for mCRPC pts. From our preliminary data, it appears that some pts characteristics are important in driving the choice of the clinicians between AA and DOC. Data collection is ongoing in other Italian hospitals.
TCT-606 Early DES and BMS healing profile assessed by OCT and proteomics in a pig model
Authors: Wojciech Wojakowski, Gonca Suna, Jonathan M. Hill, Javier Barallobre-Barreiro, Pawel Gasior, Xiaoke Yin, Tomasz Roleder, Krzysztof P. Milewski, Piotr P. Buszman, Buszman E. Pawel, Manuel Mayr
Journal: Journal of the American College of Cardiology (2015)
TCT-771 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study
Authors: Melvin Lobo, Joseph Montarello, Manish Saxena, Ajay Jain, Darren Walters, Matthew W. Pincus, Stephen G. Worthley
Journal: Journal of the American College of Cardiology (2015)
A Prognostic Role for Absolute Lymphocyte Counts in Pediatric Non- Hodgkin’s Lymphoma
Authors: Alejandro G. Levy, Romina Sabella-River, Maurizio L. Ghisoli, Cesar A. Nunez, Pete M. Anderson, Shana L Palla, Guillermo De Angulo, Patrick A. Zweidler-McKay
Journal: Blood (2008)
PARE0009 A taxonomy of disease experiences of women with SJÖGREN'S syndrome from the perspective of the patient
Authors: MY Visser-Noordegraaf, V Hiensch, G Rojas-Alcayaga, R Geenen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> In earlier studies of experiences of patients with Sjögren9s Syndrome (SS), professionals interpreted the data and drew conclusions and implications. In the current study, patients had a major share in the interpretation and structuring of experiences, and a patient research partner was part of the research group in all phases of the study: planning, collecting data, organizing, analyzing, and reporting. <h3>Objectives</h3> The aim of this study was to examine the full spectrum of life experiences of women with SS in an integrated, hierarchical model, and to examine the degree to which the research participants experienced the sorted experiences themselves. <h3>Methods</h3> Patients structured and interpreted the data using a concept mapping technique. In a card-sorting task, 52 patients with SS from the Netherlands grouped 75 experiences in piles. These experiences came from previous in-depth interviews with Chilean patients [1]. Hierarchical cluster analysis yielded an integrated, hierarchical model of these sortings. The 52 patients indicated on a 4-point Likert scale whether they had had these experiences themselves: agree, agree a little, disagree a little, disagree. <h3>Results</h3> Hierarchical cluster analyses showed a main 6-category clustering of experiences with primary symptoms, emotional processing, social interaction, self-management, ignorance, and physicians. Four of these categories showed underlying clusters of experiences (see Figure). Patients generally agreed to have common experiences of "primary symptoms", "role functioning barriers", and "diagnosis" and they commonly disagreed with the "psychologizing" symptoms, while they differed in the degree to which they had individually experienced the other experiences. <h3>Conclusions</h3> Life experiences of women with SS were summarized in an integrated, hierarchical model consisting of 14 clusters in 6 overarching categories. The results may be colored by the cultural background of the participants. This year this concept mapping study will be extended to patients from Chile, which will increase the generalizability of the findings and allow cross-cultural comparison. The final hierarchical overview with life experiences from the patient9s view can be used to improve screening in clinical consults, develop a questionnaire, give direction to future research, and enhance education and self-management support [cf. 2]. The method gives ample room to really incorporate the patient perspective in research. <h3>References</h3> Rojas-Alcayaga G et al. Illness Experiences in women with oral dryness as a result of Sjögren9s syndrome: The patient point of view. Musculoskeletal Care 2016;14: 233–42. Ammerlaan JW et al. Building a tailored, patient-guided, web-based self-management intervention 9ReumaUitgedaagd!9 for adults with a rheumatic disease. JMIR Res Protoc 2016;5:e113. <h3>Disclosure of Interest</h3> None declared
Case-cohort study to determine the value of therapeutic touch in preventing radiation dermatitis.
Authors: J. Younus, M. Lock, J. Malec, O. Vujovic, E. Yu
Journal: Journal of Clinical Oncology (2011)

103 Background: Therapeutic touch (TT) is a noninvasive healing technique. There is evidence of value in various clinical areas, but not during radiotherapy (RT) for breast cancer. The TT Cohort was designed to assess the acceptability, compliance, and side effects of TT. The Control Cohort was used compare the impact of TT in preventing radiation dermatitis. Methods: Early breast cancer patients scheduled to undergo post-conservative surgery RT were selected. TT was administered three times per week during RT. Feasibility was defined a priori as 15 of 17 patients completing all treatments. The effectiveness of TT was evaluated by the NCIC CTC V3 dermatitis scale and EORTC Cosmetic Rating. The quality of life (QOL), mood, and fatigue were assessed by EORTC QLQ C30, POMS, and BFI, respectively. These were assessed at baseline and weekly during treatment. Results: 17 stage I/II breast were prospectively identified for the TT Cohort and 31 patients were prospectively assessed in the Control Cohort. Median age was 63 years (47-79). TT was considered feasible as all 17 patients completed treatment. In the TT Cohort, the worst grade of radiation dermatitis was grade II in 9 patients. One patient did not develop any dermatitis. Median time to develop the worst grade was 20 days. QOL, mood and energy, and fatigue levels were consistent with the previous published studies. In the Control Cohort, the worst grade of radiation dermatitis was grade III in 1 patient. The most common toxicity grade was II in 15 patients. Three patients did not develop any dermatitis. Median time to develop the worst grade was 29 days. There was no statistical difference in the overall cosmetic score and grade II/III toxicity. There was a statistically significant difference in skin pigmentation and edema. Conclusions: This study represents the first evaluation of TT in patients with EBC using objective measures. TT is a feasible addition for the management of dermatitis to a tertiary clinic. TT neither improved overall cosmesis nor grade II/III toxicity.
Combination of docetaxel, cisplatin, and capecitabine (DCX) as a first-line chemotherapy in patients with metastatic gastric carcinoma: A phase II study.
Authors: Mekhty Narimanov, Alexey Tryakin, Igor Bazin, Dheepak Kanagavel, Sergei Tjulandin
Journal: Journal of Clinical Oncology (2012)

e14623 Background: Docetaxel is an active agent for treatment of metastatic gastric carcinoma. We launched this phase II trial to evaluate the efficacy and safety of docetaxel, cisplatin and capecitabine (DCX) combination in patients (pts) with metastatic gastric carcinoma. Methods: Pts with metastatic gastric carcinoma received docetaxel 75 mg/m2 i.v. day 1, cisplatin 75 mg/m2 i.v. day 1, capecitabine 1650 mg/m2 per os days 1-14 every 3 weeks. Up to 6 cycles were provided. G-CSF was not routinely used for primary prophylaxis. Results: From 2007 to 2011, 37 pts were included in the study, all pts were available for response. Pts characteristics and results are shown in the table. Median number of cycles delivered was 5 (range, 1-5). Grade 3-4 toxicity (per cycle) included: neutropenia – 24,9%, deep venous thrombosis – 2%, diarrhea – 6.2%, stomatitis – 3.8%, infection – 11%; anemia 14% pts. Six pts had dose reductions, 2 pts stopped chemotherapy due to toxicity. No toxic deaths were observed. Median progression-free survival (PFS) and median overall survival (OS) were 7,5 months (95% CI 6,076-8,857) and 14,5 months (95% CI 10,054-18,880), respectively. Conclusions: Compare with combination of docetaxel, cisplatin and 5-FU, evaluated in V325 study, our regimen had more favorable toxic profile with similar efficacy. Further investigation of this regimen in randomized controlled trials is warranted. [Table: see text]
GW27-e0796 Vitamin D level and myocardial revascularization in patients affected by peripheral artery disease: a prospective study
Authors: Giuseppe Di Stolfo, Sandra Mastroianno, Michele Antonio Pacilli, Carlo Coli, Carmela d'Arienzo, Mario Fanelli, Giovanni De Luca, Aldo Russo, Domenico Rosario Potenza, Raffaele Fanelli
Journal: Journal of the American College of Cardiology (2016)
Combination mTOR+IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors.
Authors: R. H. Quek, J. A. Morgan, G. Shapiro, J. E. Butrynski, Q. Wang, T. Huftalen, N. Jederlinic, A. J. Wagner, G. D. Demetri, S. George
Journal: Journal of Clinical Oncology (2010)

10002 Background: Preclinical models demonstrate synergistic antitumor activity with combination blockade of mTOR and IGF-IR signaling. We aimed to determine the tolerability and recommended phase II dose (RP2D) for co-administration of CP-751871, a fully human IgG2 anti-insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody (Pfizer) and the mTOR inhibitor, everolimus (Novartis). Methods: Single-center phase I investigator-held IND study in pts with advanced sarcomas and other solid tumors. Initial dose level combined the full phase II dose of CP-751871 (20mg/kg IV q21d) with conventional dose of everolimus (10mg by mouth daily). Drug doses would be de-escalated in subsequent cohorts if unacceptable rate of DLTs were observed; 15 additional patients to be enrolled at RP2D. pK data were captured on c1d1, 8, 15, and c2d1. Tumor assessments per RECIST were performed every 2 cycles. Results: No DLTs were observed in the dose-finding cohort. Therefore, full dose CP-751871 and everolimus was determined to be the RP2D. To date, 17 pts have been enrolled (3 osteosarcoma, 3 malignant SFT, 3 LMS, 8 others). Pts have received 1-7 cycles of protocol drugs with study ongoing. Median age is 56 years (range 25-77); median 4 lines of prior treatment (range 1-8). Adverse events (AE) were generally mild and well tolerated. There were no Grade 3/4 hematological AEs. Grade 3 non-hematological AEs: 1 pneumonitis, 1 nausea/vomiting, 1 diarrhea, 2 mucositis, 1 asymptomatic hypophosphatemia. There were no Grade 4 AEs. Treatment-emergent fasting hyperglycemia was observed: grade 1 (7pts) and grade 2 (3 pts). PK analysis is underway. To date, 8 patients have been evaluated for response: progression of disease (n=2), stable disease (n=6). One patient was removed from study for clinical progression after one cycle. Conclusions: Full dose combination of CP-751871 (20mg/kg IV q3wks) plus everolimus (10mg/day orally) appears safe and well tolerated with no unexpected toxicities. In this mixed population of 16 sarcoma pts (1 adrenocortical carcinoma), the majority have experienced stable disease. Additional follow-up will determine the durability of stability in specific tumor types. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, ARIAD, Genentech, Novartis, Pfizer Novartis, Pfizer ARIAD, ArQule, Exelixis, Genentech, Novartis, Pfizer, Prolexys Ariad, Novartis, Pfizer
An open label non-randomized phase II trial of erlotinib following concurrent chemo-radiotherapy as maintenance therapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study
Authors: J. Casal, S. Vázquez, F. J. Barón, J. L. Fírvida, M. Amenedo, L. Santomé, M. Lázaro, G. Alonso
Journal: Journal of Clinical Oncology (2008)

18501 Background: Based on recent studies, concurrent chemo-radiotherapy could be considered the standard treatment of stage III NSCLC pts without malignant effusions. Erlotinib is an oral EGFR TKI that has shown activity in recurrent and metastatic NSCLC. This phase II study aims to assess the activity and toxicity of the addition of erlotinib as a maintenance therapy in stage III NSCLC pts after a standard concurrent chemo-radiotherapy regimen. Methods: Pts with stage IIIA-IIIB (without malignant effusions) medically inoperable or unresectable NSCLC who had received concurrent chemo-radiotherapy and had no sign of progression disease after that treatment, performance status (PS) 0–2, adequate bone marrow, hepatic and renal function, measurable disease by RECIST criteria, and written informed consent were enrolled into this prospective open label one arm phase II study. Pts were treated with erlotinib 150 mg/day po for 6 months as maintenance therapy after standard concurrent chemo-radiotherapy. Primary endpoint of the study is the percentage of pts without evidence of disease progression after 6 months of erlotinib therapy. Results: A total of 28 pts have been recruited from March 2006 to the moment of this analysis. Data from 21 pts is available. All pts were caucasian, men 90%, median age 64 years (range 41–76), current/ever smokers 95,2%, PS 0–1 100%, histology adenocarcinoma 14.3%, squamous cell carcinoma 81%, other histologies 4.7% and stage IIIB 76,2%. 18 pts have been evaluable for response, 16,7% reached complete response, 11.1% partial response, 61,1% stable disease and 11,1% progression disease. 16 pts have ended treatment with erlotinib, of which 8 pts were treated during the 6 expected months, 3 stopped erlotinib due to adverse events (1 grade 3 rash, 1 grade 2 asthenia + grade 2 diarrhea and 1 grade 2 dyspnea + respiratory infection), 2 presented progression disease and 1 retired the informed consent. Conclusions: Erlotinib as maintenance therapy after standard concurrent chemo-radiotherapy treatment in stage III NSCLC p seems to be efficient and does not appear to increase toxicities. Data on survival will be presented. No significant financial relationships to disclose.